Protagonist Therapeutics (PTGX) Operating Leases (2019 - 2025)
Historic Operating Leases for Protagonist Therapeutics (PTGX) over the last 7 years, with Q3 2025 value amounting to $8.5 million.
- Protagonist Therapeutics' Operating Leases fell 2150.16% to $8.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 million, marking a year-over-year decrease of 2150.16%. This contributed to the annual value of $10.4 million for FY2024, which is N/A changed from last year.
- As of Q3 2025, Protagonist Therapeutics' Operating Leases stood at $8.5 million, which was down 2150.16% from $9.1 million recorded in Q2 2025.
- Protagonist Therapeutics' 5-year Operating Leases high stood at $11.0 million for Q2 2024, and its period low was $462000.0 during Q1 2023.
- In the last 5 years, Protagonist Therapeutics' Operating Leases had a median value of $4.1 million in 2021 and averaged $5.6 million.
- Per our database at Business Quant, Protagonist Therapeutics' Operating Leases tumbled by 1324.46% in 2021 and then tumbled by 8491.18% in 2023.
- Over the past 5 years, Protagonist Therapeutics' Operating Leases (Quarter) stood at $3.7 million in 2021, then plummeted by 68.81% to $1.1 million in 2022, then tumbled by 59.51% to $462000.0 in 2023, then surged by 2141.56% to $10.4 million in 2024, then decreased by 17.72% to $8.5 million in 2025.
- Its Operating Leases stands at $8.5 million for Q3 2025, versus $9.1 million for Q2 2025 and $9.8 million for Q1 2025.